Search Results

IO Biotech announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York.

IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024.

IO Biotech today announced that Faiçal Miyara, Ph.D., has been appointed as the company’s chief business officer.

IO Biotech (Nasdaq: IOBT) today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.